Pseudopelade of Brocq in a child

Bulengo-Ransby, Stella M.; Headington, John T.

doi:10.1016/s0190-9622(08)80706-2

Cited by 25 publications

(14 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, the task of objectively monitoring therapeutic efficacy in a condition that usually has no overt signs of inflammation and is often asymptomatic can almost be impossible. 10 Variable success has been reported with topical corticosteroids, 2,7,10 intralesional triamcinolone acetonide (10 mg/mL), 2,7,10,121 prednisone, 10 hydroxychloroquine, 2,7,10,198 and isotretinoin, 10 with little detail on protocol. At the University of British Columbia hair clinic, pseudopelade of Brocq is managed similarly to lichen planopilaris with no single modality of exceptional benefit.…”

Section: Graham-little Syndromementioning

confidence: 99%

Update on primary cicatricial alopecias

Ross

Tan

Shapiro

2005

Journal of the American Academy of Dermatology

256

323

View full text Add to dashboard Cite

Section: Graham-little Syndromementioning

confidence: 99%

Update on primary cicatricial alopecias

Ross

Tan

Shapiro

2005

Journal of the American Academy of Dermatology

256

323

View full text Add to dashboard Cite

“…Pseudopelade may not be an uncommon occurrence in children and it is important to bear in mind this diagnosis whenever one encounters a child with patchy alopecia. 17 However, the majority of pseudopelade behaves in an insidious manner and is rarely inflammatory. 1,15 In our experience, pseudopelade is a great mimicker of many hair-loss conditions.…”

Section: Lymphocytic Cicatricial Alopeciasmentioning

confidence: 99%

Primary cicatricial alopecias: clinicopathology of 112 cases

Tan

Martinka

Ball

et al. 2004

Journal of the American Academy of Dermatology

221

252

View full text Add to dashboard Cite

“…Bulengo‐Ransby and Headington 200 reported a child who improved with hydroxychloroquine. They claimed, in their experience, that hydroxychloroquine is the only effective treatment for PB; however, no further information was supplied 201 .…”

Section: Lymphocytic Groupmentioning

confidence: 99%

Management of primary cicatricial alopecias: options for treatment

et al. 2008

View full text Add to dashboard Cite

Primary cicatricial alopecias (PCAs) are a poorly understood group of disorders that result in permanent hair loss. Clinically, they are characterized not only by permanent loss of hair shafts but also of visible follicular ostia along with other visible changes in skin surface morphology, while their histopathological hallmark usually (although not always) is the replacement of follicular structures with scar-like fibrous tissue. As hair follicle neogenesis in adult human scalp skin is not yet a readily available treatment option for patients with cicatricial alopecias, the aim of treatment, currently, remains to reduce symptoms and to slow or stop PCA progression, namely the scarring process. Early treatment is the key to minimizing the extent of permanent alopecia. However, inconsistent terminology, poorly defined clinical end-points and a lack of good quality clinical trials have long made management of these conditions very challenging. As one important step towards improving the management of this under-investigated and under-serviced group of dermatoses, the current review presents evidence-based guidance for treatment, with identification of the strength of evidence, and a brief overview of clinical features of each condition. Wherever only insufficient evidence-based advice on PCA management can be given at present, this is indicated so as to highlight important gaps in our clinical knowledge that call for concerted efforts to close these in the near future.

show abstract

Pseudopelade of Brocq in a child

Cited by 25 publications

References 3 publications

Update on primary cicatricial alopecias

Update on primary cicatricial alopecias

Primary cicatricial alopecias: clinicopathology of 112 cases

Management of primary cicatricial alopecias: options for treatment

Contact Info

Product

Resources

About